Additionally, multiple reports and a phase I study have demonstrated the efficacy of IL-6 blockade in refractory arthritis or serositis, emphasizing its role in the pathophysiology of SLE (109–113). This evidence concerns the gene IL6 and systemic lupus erythematosus.